- Home
- CPOP vs BMEA Comparison
CPOP vs BMEA Comparison
Compare CPOP & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPOP
- BMEA
- Stock Information
- Founded
- CPOP 2007
- BMEA 2017
- Country
- CPOP China
- BMEA United States
- Employees
- CPOP N/A
- BMEA N/A
- Industry
- CPOP Services-Misc. Amusement & Recreation
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- CPOP Consumer Discretionary
- BMEA Health Care
- Exchange
- CPOP Nasdaq
- BMEA Nasdaq
- Market Cap
- CPOP 98.5M
- BMEA 114.3M
- IPO Year
- CPOP 2021
- BMEA 2021
- Fundamental
- Price
- CPOP $1.64
- BMEA $1.94
- Analyst Decision
- CPOP
- BMEA Strong Buy
- Analyst Count
- CPOP 0
- BMEA 11
- Target Price
- CPOP N/A
- BMEA $16.55
- AVG Volume (30 Days)
- CPOP 1.3M
- BMEA 543.8K
- Earning Date
- CPOP 10-28-2025
- BMEA 10-28-2025
- Dividend Yield
- CPOP N/A
- BMEA N/A
- EPS Growth
- CPOP N/A
- BMEA N/A
- EPS
- CPOP N/A
- BMEA N/A
- Revenue
- CPOP $65,186,721.00
- BMEA N/A
- Revenue This Year
- CPOP N/A
- BMEA N/A
- Revenue Next Year
- CPOP N/A
- BMEA N/A
- P/E Ratio
- CPOP N/A
- BMEA N/A
- Revenue Growth
- CPOP 108.29
- BMEA N/A
- 52 Week Low
- CPOP $0.46
- BMEA $1.29
- 52 Week High
- CPOP $2.47
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- CPOP 73.15
- BMEA 56.11
- Support Level
- CPOP $1.15
- BMEA $1.77
- Resistance Level
- CPOP $2.13
- BMEA $2.08
- Average True Range (ATR)
- CPOP 0.19
- BMEA 0.11
- MACD
- CPOP 0.04
- BMEA 0.01
- Stochastic Oscillator
- CPOP 51.96
- BMEA 54.84
About CPOP Pop Culture Group Co. Ltd
Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.